CA3084034C - Covalent anesthetic-polymer conjugates for prolonged local anesthesia - Google Patents

Covalent anesthetic-polymer conjugates for prolonged local anesthesia Download PDF

Info

Publication number
CA3084034C
CA3084034C CA3084034A CA3084034A CA3084034C CA 3084034 C CA3084034 C CA 3084034C CA 3084034 A CA3084034 A CA 3084034A CA 3084034 A CA3084034 A CA 3084034A CA 3084034 C CA3084034 C CA 3084034C
Authority
CA
Canada
Prior art keywords
ttx
anesthetic
peg
pgs
polymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3084034A
Other languages
English (en)
French (fr)
Other versions
CA3084034A1 (en
Inventor
Daniel S. Kohane
Chao Zhao
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CHILREN'S MEDICAL CENTER Corp
Original Assignee
CHILREN'S MEDICAL CENTER Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CHILREN'S MEDICAL CENTER Corp filed Critical CHILREN'S MEDICAL CENTER Corp
Publication of CA3084034A1 publication Critical patent/CA3084034A1/en
Application granted granted Critical
Publication of CA3084034C publication Critical patent/CA3084034C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • A61P23/02Local anaesthetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Anesthesiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3084034A 2017-12-01 2018-12-03 Covalent anesthetic-polymer conjugates for prolonged local anesthesia Active CA3084034C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762593784P 2017-12-01 2017-12-01
US62/593,784 2017-12-01
PCT/US2018/063573 WO2019109065A1 (en) 2017-12-01 2018-12-03 Covalent anesthetic-polymer conjugates for prolonged local anesthesia

Publications (2)

Publication Number Publication Date
CA3084034A1 CA3084034A1 (en) 2019-06-06
CA3084034C true CA3084034C (en) 2022-08-16

Family

ID=64734233

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3084034A Active CA3084034C (en) 2017-12-01 2018-12-03 Covalent anesthetic-polymer conjugates for prolonged local anesthesia

Country Status (7)

Country Link
US (2) US20210275678A1 (enExample)
EP (1) EP3717017A1 (enExample)
JP (2) JP7601375B2 (enExample)
CN (1) CN111867633B (enExample)
AU (1) AU2018375002B2 (enExample)
CA (1) CA3084034C (enExample)
WO (1) WO2019109065A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4090374A4 (en) * 2020-01-17 2024-10-09 Children's Medical Center Corporation MACROMOLECULAR PRODRUGS FOR LIGHT EMITTING DIODES AND THEIR USES
CN113805326A (zh) * 2021-09-18 2021-12-17 吉林大学 原位拉伸多光子激光共聚焦成像仪、实时原位三维观测共混聚合物内部结构的方法
US20250099421A1 (en) * 2023-09-27 2025-03-27 Relevium Medical Analgesic Therapeutics Based on conjugation of Biocompatible Polymers to Ion Channel Modulators
CN119345382B (zh) * 2024-12-23 2025-03-21 上海华之沃生物医药科技有限公司 替曲朵辛偶联物、制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4001413A (en) 1973-06-12 1977-01-04 Astra Pharmaceutical Products, Inc. Pharmaceutical local anesthetic composition employing saxitoxin
US5700485A (en) * 1992-09-10 1997-12-23 Children's Medical Center Corporation Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid
US6326020B1 (en) * 1997-05-16 2001-12-04 Children's Medical Center Corporation Local anesthetic formulations
GB0218830D0 (en) * 2002-08-13 2002-09-18 Syngenix Ltd Anaesthetic conjugate
US20040228831A1 (en) 2003-05-15 2004-11-18 Belinka Benjamin A. Polymeric conjugates for tissue activated drug delivery
US8980317B2 (en) * 2008-12-23 2015-03-17 Warsaw Orthopedic, Inc. Methods and compositions for treating infections comprising a local anesthetic
EA201171195A8 (ru) * 2009-03-30 2014-08-29 Серулин Фарма Инк. Конъюгаты, частицы, композиции "полимер-агент" и способы их применения
KR20140057414A (ko) 2011-06-22 2014-05-12 바이옴 바이오사이언스 피브이티. 엘티디. 컨쥬게이트계 항진균 및 항세균 프로드러그
US9408846B2 (en) * 2012-04-23 2016-08-09 The Children's Medical Center Corporation Formulations and methods for delaying onset of chronic neuropathic pain
ES2727292T3 (es) * 2013-03-15 2019-10-15 Childrens Medical Ct Corp Formulaciones combinadas de neosaxitonina para una anestesia local prolongada
US10449152B2 (en) * 2014-09-26 2019-10-22 Covidien Lp Drug loaded microspheres for post-operative chronic pain
CN106310289B (zh) * 2015-06-24 2020-10-13 天津键凯科技有限公司 一种聚乙二醇和麻醉药的结合物及其制备方法

Also Published As

Publication number Publication date
CA3084034A1 (en) 2019-06-06
WO2019109065A1 (en) 2019-06-06
JP2024114970A (ja) 2024-08-23
CN111867633A (zh) 2020-10-30
US20210275678A1 (en) 2021-09-09
AU2018375002B2 (en) 2021-11-11
AU2018375002A1 (en) 2020-07-02
EP3717017A1 (en) 2020-10-07
JP2021505550A (ja) 2021-02-18
JP7601375B2 (ja) 2024-12-17
CN111867633B (zh) 2023-09-22
US20250195671A1 (en) 2025-06-19

Similar Documents

Publication Publication Date Title
US20250195671A1 (en) Covalent anesthetic-polymer conjugates for prolonged local anesthesia
Zhang et al. Long-acting hydrogel/microsphere composite sequentially releases dexmedetomidine and bupivacaine for prolonged synergistic analgesia
CA2843503C (en) Polymeric hyperbranched carrier-linked prodrugs
RU2554854C9 (ru) Биоразлагаемые нерастворимые в воде гидрогели на основе полиэтиленгликоля
RU2607498C2 (ru) Жидкотекучие композиции для инъекций, включающие бупренорфин
Sandker et al. In situ forming acyl-capped PCLA–PEG–PCLA triblock copolymer based hydrogels
US20140219923A1 (en) Biodegradable compositions suitable for controlled release
Zhang et al. Sustained release of levobupivacaine from temperature-sensitive injectable hydrogel for long-term local anesthesia in postoperative pain management
IL190486A (en) Compounds of hydrophobic polymers undergoing glaciation and containing radical acid and their uses
AU2011294295A1 (en) Crosslinked hyaluronic acid composition and self-crosslinking hyaluronic acid particles
CA2926169C (fr) Compositions a liberation continue a base d'acide hyaluronique, et leurs applications therapeutiques
EP3068373B1 (en) Aqueous based capsaicinoid formulations and methods of manufacture and use
US20090324741A1 (en) Injectable polymer-lipid blend
AU2012289968A1 (en) Stable anti-inflammatory solutions for injection
KR20190143555A (ko) 카토제닌 유도체를 포함하는 고분자 미셀, 히알루론산 하이드로겔 및 이의 제조방법 및 그 용도
EP3285761B1 (en) Parthenolide and its derivatives for use in the treatment of axonal damage
KR20230161453A (ko) 약제학적 조성물
US20250099598A1 (en) Analgesic Therapeutics Based on Conjugation of Biocompatible Polymers to Ion Channel Modulators
Zhong et al. Anti-inflammatory effect of a novel piperazino-enaminone delivered by liposomes in a mouse model of hemophilic arthropathy
KR102062690B1 (ko) 이미다졸-폴리(유기포스파젠) 하이드로겔을 포함하는 척수 손상 예방 또는 치료용 조성물
Pastukh et al. Injectable hyaluronic acid–metformin conjugate gel for sustained intra‐articular delivery and prevention of post‐traumatic osteoarthritis
WO2025068983A1 (en) Analgesic therapeutics based on conjugation of biocompatible polymers to ion channel modulators
Shao et al. A pH-responsive injectable hydrogel that modulates the inflammatory microenvironment for the treatment of osteoarthritis
Johnston Development of Dendritic Polymers as a Modular Drug Delivery Platform for Avascular Tissues
WO2024254258A2 (en) Method of treating an articular condition or a condition of a bony canal

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200529

EEER Examination request

Effective date: 20200529